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1. Introduction
Since the discovery of heparin in 1915, anticoagulant drugs have played a vital 
role in prophylaxis of deep vein thrombosis and pulmonary thromboembolism 
among other important indications, and for more than six decades, both heparin 
and coumarins especially warfarin have been the principal drugs used for antico-
agulation worldwide [1, 2]. In the mid-1970s and the 1980s, several low-molecular-
weight heparins have been clinically trialed and commercialized, and over the 
past few decades, parenteral direct thrombin inhibitors (DTIs) (e.g., argatroban, 
bivalirudin), oral DTIs (e.g., dabigatran), and oral direct factor Xa inhibitors (e.g., 
rivaroxaban) have also been introduced into the clinical practice to cope with the 
growing use of anticoagulants in medicine [1, 3, 4].
The clinical practice involving the use of anticoagulants, e.g., dosing, timing, 
and managing complications, has been a real challenge even to some of the best 
experts in the field mainly due to their potential to cause serious adverse effects, 
both hemorrhagic and nonhemorrhagic which may occur with all the currently used 
anticoagulants regardless of their year of discovery [2, 5–8].
Thus, in this book you’ll find experts’ opinion providing state-of-art knowledge 
regarding current clinical usage and monitoring of anticoagulant therapy. It dis-
cusses some very critical subjects like the mechanism and heterogenic presentation 
of heparin-induced thrombocytopenia, laboratory monitoring of heparin anticoag-
ulants, quality of life among patients, as well as an updated pharmacological review 
of the currently used anticoagulants and their antidotes. Our main aim is to improve 
the clinical practice of all physicians and healthcare providers who are dealing with 
anticoagulants as well as to present an added value to the current literature discuss-
ing the complications experienced while using anticoagulants. We’re still waiting 
for the synthesis of an ideal or almost ideal anticoagulant which combines both 
efficacy and lack of serious adverse effects [9].
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